High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset. - Wikidata - wikimedia - TriplyDB

High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset.

High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset.

http://www.wikidata.org/entity/Q33732709

about

CLImAT: accurate detection of copy number alteration and loss of heterozygosity in impure and aneuploid tumor samples using whole-genome sequencing data.Comprehensive SNP array study of frequently used neuroblastoma cell lines; copy neutral loss of heterozygosity is common in the cell lines but uncommon in primary tumors nbCNV: a multi-constrained optimization model for discovering copy number variants in single-cell sequencing data 11q deletion in neuroblastoma: a review of biological and clinical implications.Glycobiology of neuroblastoma: impact on tumor behavior, prognosis, and therapeutic strategies.A statistical approach for detecting genomic aberrations in heterogeneous tumor samples from single nucleotide polymorphism genotyping data The role of complex genomic alterations in neuroblastoma risk estimation.Ultra-High Density SNParray in Neuroblastoma Molecular Diagnostics Control-FREEC: a tool for assessing copy number and allelic content using next-generation sequencing data Autocrine prostaglandin E2 signaling promotes tumor cell survival and proliferation in childhood neuroblastoma.Neuroblastoma after childhood: prognostic relevance of segmental chromosome aberrations, ATRX protein status, and immune cell infiltration Tumor development, growth characteristics and spectrum of genetic aberrations in the TH-MYCN mouse model of neuroblastoma.Genetic instability and intratumoral heterogeneity in neuroblastoma with MYCN amplification plus 11q deletion.Age dependence of tumor genetics in unfavorable neuroblastoma: arrayCGH profiles of 34 consecutive cases, using a Swedish 25-year neuroblastoma cohort for validation.Metabolic characteristics of 13-cis-retinoic acid (isotretinoin) and anti-tumour activity of the 13-cis-retinoic acid metabolite 4-oxo-13-cis-retinoic acid in neuroblastoma.Aneuploidy in neuroblastoma tumors is not associated with inactivating point mutations in the STAG2 gene Sequential dosing in chemosensitization: targeting the PI3K/Akt/mTOR pathway in neuroblastoma.Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study).Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification.Correlation between the International Neuroblastoma Pathology Classification and genomic signature in neuroblastoma.Copy number losses define subgroups of dedifferentiated liposarcoma with poor prognosis and genomic instability.The role of intracellular calcium for the development and treatment of neuroblastoma.Insights into the Molecular Pathogenesis of Activated B-Cell-like Diffuse Large B-Cell Lymphoma and Its Therapeutic Implications.COX/mPGES-1/PGE2 pathway depicts an inflammatory-dependent high-risk neuroblastoma subset.Serum-Based Quantification of MYCN Gene Amplification in Young Patients with Neuroblastoma: Potential Utility as a Surrogate Biomarker for Neuroblastoma.High genomic instability predicts survival in metastatic high-risk neuroblastoma.The RASSF gene family members RASSF5, RASSF6 and RASSF7 show frequent DNA methylation in neuroblastoma.Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project Genome-wide methylation profiling identifies novel methylated genes in neuroblastoma tumors The microenvironment of human neuroblastoma supports the activation of tumor-associated T lymphocytes Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma.The genetic tumor background is an important determinant for heterogeneous MYCN-amplified neuroblastoma.ERBB3 is a marker of a ganglioneuroblastoma/ganglioneuroma-like expression profile in neuroblastic tumours.Molecular inversion probe analysis detects novel copy number alterations in Ewing sarcoma Neuroblastoma and MYCN Precise inference of copy number alterations in tumor samples from SNP arrays.Co-expression analysis identifies long noncoding RNA SNHG1 as a novel predictor for event-free survival in neuroblastoma.Genetic stratification of neuroblastoma for treatment tailoring.The role of genetic and epigenetic alterations in neuroblastoma disease pathogenesis.New insights into the genetics of neuroblastoma.

P2860

Q30824888-ADB1340C-FDFA-4C5F-8D8D-8861ADA3A218 Q31030415-79B76B77-7CA7-4629-A863-EE8E732CAF7A Q31131418-375CD46D-1FA0-4474-B13A-708CD7724EF8 Q32174267-4E1312C3-C6DA-4723-9723-C1B42454B157 Q33659849-B95DC399-5366-46A0-87BB-CE918779C8D2 Q33698545-5783947E-DB1C-4745-B6E2-AE37588F6781 Q33918821-01BDBD7F-D964-455D-81A7-44B0B0E8DDAC Q34032495-F6D3A78D-BAD2-412A-A7AB-0C19135D7AF1 Q34095905-9D95F87A-18E5-413C-931A-CAE818D4BD2D Q34140169-26D5C283-0369-402E-852B-59F268446C5F Q34346730-91B5725B-03DE-4AC4-B5F8-9D31C57331DC Q34531771-6C0AA39F-7C00-463C-8315-C5D9910D5A8E Q34558670-EA146B47-5945-416B-8476-2AB5FA891950 Q34711056-840C182A-914A-4866-BB1E-42B8B215A549 Q34953372-A949C44A-6202-40B4-B1F2-B5FEE6F6A8B1 Q35006926-6A293632-9438-4EA4-8E3E-04C06FE5C102 Q35082400-696A24C2-1BF6-4621-990D-B7D856D7380D Q35653969-B896D8FF-1AC7-43FA-B63B-9ED9892DEE6E Q35677257-1172675B-97F1-46A3-A737-E6874B0995AC Q35754243-2FA40E77-D5DC-465E-B430-1AC1B83FC36C Q35803084-2670492C-58BA-4B82-88C8-E3A386A58306 Q35818437-E35E75C6-717D-41A9-8B50-897700745CCE Q35818443-DE8E41A9-8A95-457C-B5C1-525BA9ECBE09 Q35818767-AF3A7EE9-FBAB-4375-B70A-3E8DE203C20E Q36101495-13243FB8-4108-4074-9D5C-BCE59022759B Q36282735-A9C56C97-B14F-4CC6-9039-DDE0E4DE9B66 Q36383883-7AD4CFF0-8014-4A67-BC43-E5FE9A2630C6 Q36387812-58FDE010-523E-4A7C-97B5-64F6EF17E060 Q36838937-8CC0CC31-6B4D-4A55-90C9-365C7C3EA562 Q36866183-CD4E40D8-27B7-4ED6-83FD-690EE09A1B88 Q36910335-7EB18EB8-95ED-471C-81DF-CB9E9282290B Q37105296-82CA48EA-D1C8-4388-99BC-0768939DBEE2 Q37154010-E3F0F3BD-4A84-4B65-A540-955CDC68F630 Q37200438-F9E70ABA-08C4-45C3-95A1-EE1B8A376EF7 Q37201479-9CAE7C3E-D0B1-4F0A-A2C4-661A498423B5 Q37327531-6A295014-A3EB-4114-A65A-2FCCFF7D41E0 Q37628972-3FBBEA64-9E5D-4D51-93AE-448D27F0A074 Q37932545-9CE1781D-A2F2-4CD4-B192-D3A4C627D447 Q38070334-B3B713DF-0A9F-4A30-A42D-E6A57C46DCBD Q38074875-F215153C-D84C-4A08-A08A-2A09DB6E4B08

P2860

High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset.

http://www.wikidata.org/entity/Q33732709

description

2010 nî lūn-bûn

@nan

2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

High-risk neuroblastoma tumors ...... ty phenotype with later onset.

@ast

High-risk neuroblastoma tumors ...... ty phenotype with later onset.

@en

type

label

High-risk neuroblastoma tumors ...... ty phenotype with later onset.

@ast

High-risk neuroblastoma tumors ...... ty phenotype with later onset.

@en

prefLabel

High-risk neuroblastoma tumors ...... ty phenotype with later onset.

@ast

High-risk neuroblastoma tumors ...... ty phenotype with later onset.

@en

P1433

Q33732709-FED1D0E9-A1EC-4F4E-B5D4-610E3CE25616

P1476

Q33732709-50AF4213-0F98-4733-8F62-F8C8FFE2893A

P2093

Q33732709-02D093BA-ED8C-4F0B-A300-4F5313A4F58C

Q33732709-11192733-DDCE-4258-ACF0-8AC16E1663A4

Q33732709-5E2B12A2-B770-4BAB-9FCA-4FF96837D57F

Q33732709-65818D9F-FDA9-40EA-B575-9C52D0F374E9

Q33732709-7841DDA7-4299-40D9-8124-19E8431AFA33

Q33732709-CDB911B5-53EC-43F7-97A6-A101F3363D99

P2860

Q33732709-029DBC8A-8252-404D-8992-A4AEDD08D220

Q33732709-12CE63E7-5C1E-4165-BDEB-329202738A3E

Q33732709-1A9C430C-E83F-480D-8332-894B0547E0D7

Q33732709-1AB90D4F-FF8B-4B09-9598-274245B9F173

Q33732709-1DE5B244-8909-40C8-AF1C-65E7FDCF4547

Q33732709-1E1BF546-DFA8-4570-85CE-E6BA813A3905

Q33732709-2E869D9D-B8BF-4BF3-841C-128FFC6D30EA

Q33732709-3AC2238D-878C-4CB7-BE03-83FFFC93E326

Q33732709-40222521-8A70-476A-9F31-32D2C86D13DE

Q33732709-81AA910F-E462-455B-85DB-61BF290A8A39

P304

Q33732709-49D38037-C92F-4215-9605-2AD7404C9E2A

P31

Q33732709-03C363D7-C204-46F4-A113-1E46E083C390

P356

Q33732709-934B921C-CA1B-4195-A09D-B05063722A57

P407

Q33732709-117C6655-DA0F-4C7F-AEBF-556C6751ED9D

P433

Q33732709-B1E1EABB-F00E-4668-918B-824E9F0E2176

P478

Q33732709-D24C0442-4A33-4EA8-B6D1-333336F28DC4

P50

Q33732709-0C63C2C9-AE57-4DD1-9B98-6A6FC87C1297

Q33732709-79AD02E3-9134-44A9-BA77-D7F526162960

Q33732709-EECCB1D5-F7DB-4F52-957C-34E4E4592BD9

P577

Q33732709-4CE50ADD-9913-4138-9AA2-40C7AED205A2

P5875

Q33732709-331920E2-B3B5-4577-8DA4-4982306E974A

P698

Q33732709-BDEFF9D9-678D-4183-867B-2070E6E4BBB8

P932

Q33732709-AC0041B3-9868-408B-A76B-4B816EA7E910

P356

PNAS.0910684107

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

High-risk neuroblastoma tumors ...... ty phenotype with later onset.

@en

P2093

Catarina Träger

http://www.w3.org/2001/XMLSchema#string

Hanna Kryh

http://www.w3.org/2001/XMLSchema#string

Jonas Abrahamsson

http://www.w3.org/2001/XMLSchema#string

Maria Nethander

http://www.w3.org/2001/XMLSchema#string

Per Kogner

http://www.w3.org/2001/XMLSchema#string

Rose-Marie Sjöberg

http://www.w3.org/2001/XMLSchema#string

P2860

Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarrays

cDNA array-CGH profiling identifies genomic alterations specific to stage and MYCN-amplification in neuroblastoma

Combined subtractive cDNA cloning and array CGH: an efficient approach for identification of overexpressed genes in DNA amplicons

High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors: four cases of homozygous deletions of the CDKN2A gene.

Neuroblastoma: biological insights into a clinical enigma.

Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.

Analysis of chromosome breakpoints in neuroblastoma at sub-kilobase resolution using fine-tiling oligonucleotide array CGH.

Genome wide measurement of DNA copy number changes in neuroblastoma: dissecting amplicons and mapping losses, gains and breakpoints.

Overall genomic pattern is a predictor of outcome in neuroblastoma.

Neuroblastoma: biology and molecular and chromosomal pathology.

P304

4323-4328

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0910684107

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

107

http://www.w3.org/2001/XMLSchema#string

P50

Tommy Martinsson

Staffan Nilsson

P577

2010-02-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41419508

http://www.w3.org/2001/XMLSchema#string

P698

20145112

http://www.w3.org/2001/XMLSchema#string

P932

2840092

http://www.w3.org/2001/XMLSchema#string